Condition

CAR-T Cell Therapy clinical trials and research

• 19Clinical trials
• 74NIH research projects
• 1New in 30 days
• 5Countries

Newest CAR-T Cell Therapy clinical trials

All recruiting trials (19)

• CAR-T Therapy Safety, Response, and Immune-Escape: Observational Study in Adults

  This observational study looks at adults who receive CAR-T cell therapy or bispecific antibodies to see which factors predict response and immune-related side effects.

  Recruiting IRCCS San Raffaele · Milan, Italy · NCT07915102

• Long-Term Follow-Up of Gene Therapy Patients Treated at Seattle Children's

  This long-term follow-up study tests the safety of Seattle Children's Therapeutics gene therapy products in people who have already received at least one infusion, for up to 15 years after their last treatment.

  Recruiting Seattle Children's Hospital · Seattle, Washington · NCT07424157

• Zamtocabtagene autoleucel (MB-CART2019.1) for relapsed or refractory diffuse large B‑cell lymphoma in Japan

  This study will test a dual-target CAR T-cell therapy (MB-CART2019.1) that targets CD19 and CD20 in people in Japan whose diffuse large B‑cell lymphoma has returned or not responded after at least two prior therapies.

  Recruiting at 2 sites Phase 2 Miltenyi Biomedicine GmbH · Tokyo and 4 other locations · NCT07288879

• TC-D101 CAR-T therapy for DLL3-positive small cell lung cancer

  This trial will try a single infusion of TC-D101 CAR-T cells in adults with DLL3-positive relapsed or refractory small cell lung cancer who have progressed after prior treatments.

  Recruiting Early Phase 1 TCRCure Biopharma Ltd. · Nanjing, Jiangsu · NCT07246304

• A-CAR028 for relapsed or refractory acute myeloid leukemia

  This study will try A-CAR028, a CAR-T cell therapy, in adults with relapsed or refractory AML to see if it is safe and helps control the leukemia.

  Recruiting Phase 1 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07198867

• MB-CART2019.1 for refractory multiple sclerosis

  This trial will test a CAR T-cell therapy called MB-CART2019.1 to see if it is safe and helps adults with active, treatment‑resistant primary or secondary progressive multiple sclerosis.

  Recruiting Phase 1/2 Miltenyi Biomedicine GmbH · Berlin · NCT07178431

• Anti‑CD19 CAR‑T plus a BTK inhibitor for newly diagnosed high‑risk CLL/SLL

  We will try combining anti‑CD19 CAR‑T cells with a BTK inhibitor as first‑line treatment for people newly diagnosed with high‑risk CLL or SLL.

  Recruiting The Affiliated Hospital of Xuzhou Medical University · Xuzhou, Jiangsu · NCT07120633

• Brain scans and blood tests to spot neurotoxicity after CAR T-cell therapy

  This project will try brain MRIs, cognitive tests, and blood biomarkers to see if we can identify which adults receiving CAR T-cell therapy will develop neurotoxicity (ICANS).

  Recruiting University of California, San Diego · La Jolla, California · NCT07075523

• BCMA/CD70 CAR-T therapy for treating severe lupus in children

  This study is testing a new CAR-T cell therapy to see if it can help children and young adults with severe lupus who haven't responded well to other treatments.

  Recruiting Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT06934447

• Evaluating brain function and psychological effects of cell therapy in autoimmune hemolytic anemia

  This study is testing how CAR T-cell therapy affects thinking and mental health in people with autoimmune hemolytic anemia to help improve their treatment and quality of life.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06921980

• Providing food assistance to patients undergoing cancer treatment

  This study is testing whether giving food bags to cancer patients who struggle with food insecurity can help improve their nutrition and treatment outcomes.

  Recruiting University of Kansas Medical Center · Stanford, California and 3 other locations · NCT06802406

• THRIVE-CAR-T mobile app to support people receiving CAR T therapy

  The trial will test whether the THRIVE-CAR-T mobile app helps adults receiving CAR T-cell therapy manage symptoms, improve quality of life, and feel more confident in their care.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT06665295

• Using exercise to enhance immune cell therapy for blood cancer

  This study tests if a short cycling exercise can improve immune cells from healthy donors to help treat blood cancers like leukemia and lymphoma more effectively.

  Recruiting Early Phase 1 University of Arizona · Tucson, Arizona · NCT06643221

• Coping skills training for patients after stem cell transplant

  This study is testing a new coping skills program to see if it helps people who have had a stem cell transplant manage pain, fatigue, and stress better than usual care.

  Recruiting Duke University · Durham, North Carolina · NCT06575712

• Examining extracellular vesicles in patients receiving CAR-T cell therapy

  This study is trying to find out if certain tiny particles in the blood can help predict how well CAR-T cell therapy will work and if it will cause side effects in people with tough blood cancers.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bologna · NCT06554951

• CAR-T cell therapy for treating multi-drug resistant nephrotic syndrome

  This study is testing a new CAR-T cell therapy to see if it can help children and adults with hard-to-treat nephrotic syndrome feel better and avoid kidney failure.

  Recruiting Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT06553898

• CAR-γδT cell therapy targeting GPC3 and Mesothelin for cancer treatment

  This study is testing a new cancer treatment that uses modified immune cells to target specific proteins in patients with advanced solid tumors.

  Recruiting Phase 1 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT06196294

• Dual Target CAR-T Therapy for Refractory SLE

  This early phase study tests a CD19-BCMA CAR-T cell treatment to see if it is tolerable and potentially beneficial for adults with difficult-to-treat systemic lupus erythematosus.

  Recruiting Early Phase 1 RenJi Hospital · Shanghai, Shanghai Municipality · NCT05858684

• CAR-T cell therapy targeting mesothelin for cancer treatment

  This study is testing a new CAR-T cell therapy that targets a specific protein in advanced cancers, like pancreatic cancer, to see if it can help patients feel better and fight their disease.

  Recruiting Phase 1 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT05779917

NIH-funded research (newest 40 of 74)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• SynthNode: A new, easier way to make CAR T cells for better cancer treatment

  A new implantable device called SynthNode could simplify and lower the cost of CAR T cell therapy, helping patients with lymphoma, myeloma, and potentially solid tumors or lupus.

  NIH research Persistence Therapeutics, INC. · Chapel Hill, United States · NIH-11457453

• Intraperitoneal CAR T cells for peritoneal mesothelioma

  A new approach uses CAR T cells delivered directly into the abdominal cavity to target mesothelioma, aiming to help people whose disease is confined to the abdomen.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11443990

• Photobiomodulation to Boost CAR-T Cell Therapy for B-Cell Cancers

  A patient-facing overview of using light-based therapy to improve CAR-T cell treatment for B-cell cancers, aiming for better effectiveness and lower costs.

  NIH research Case Western Reserve University · Cleveland, United States · NIH-11437508

• Targeting death receptors to boost MET-CAR T cells for glioblastoma

  Aims to make MET-CAR T cells work better against glioblastoma by using radiation to trigger death receptors on tumor cells.

  NIH research East Tennessee State University · Johnson City, United States · NIH-11424532

• CTO1681: reducing dangerous immune reactions in patients getting CAR T-cell therapy

  A new oral drug (CTO1681) aims to prevent and lessen cytokine release syndrome in patients with blood cancers treated with CAR T-cell therapy.

  NIH research Cytoagents, INC. · Pittsburgh, United States · NIH-11418976

• CD2-targeted CAR-T therapy for T-cell lymphoma in a multi-center program

  A patient-focused overview of a research grant that aims to improve CAR-T cell therapy for T-cell lymphoma by exploring CD2 as a new target and enhancing allogeneic CAR-T safety features.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11418402

• B7-H3 CAR-T therapy for pancreatic cancer in a phase I study

  A new CAR-T treatment targeting B7-H3 is being tested in people with pancreatic cancer to see if it is safe and helps fight tumors.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11416754

• Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer

  A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-11415651

• Improving durability of responses after CAR T therapy for myeloma

  This grant explores new CAR T cell approaches to keep multiple myeloma patients in remission longer after initial treatment success.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11413794

• Next-gen genetic engineering of CD45 to boost CAR-T therapy for blood cancers

  A research team is developing a way to make CAR-T cells work for many blood cancers by re-engineering a common blood cell protein called CD45.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11413787

• Neutralizing IFN-I to boost HIV-targeted CAR T cell therapy

  A new approach aims to block a specific immune signal (IFN-I) to help HIV-fighting CAR T cells work better in people living with HIV who are on ART.

  NIH research Wistar Institute · Philadelphia, United States · NIH-11411740

• CAR T therapy for metastatic triple-negative breast cancer (TNBC) targeting B7-H3

  A new therapy using patient's own CAR T cells to fight metastatic TNBC by targeting the B7-H3 protein.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11411402

• IgG Immunoglobulin Replacement After CAR-T Therapy in B-cell Cancer Patients

  This study tests whether giving immunoglobulin replacement after CAR-T therapy reduces infections in adults with B-cell cancers.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-11397701

• Revolutionizing CAR T-cell Therapy with a Universal CAR-Enhancer Platform

  A new approach aims to make CAR T-cell therapy work longer and better for blood cancers by using a universally compatible CAR-Enhancer that helps CAR T-cells persist and fight longer.

  NIH research Koi Biotherapeutics INC. · Newark, United States · NIH-11391052

• Improving CAR T-cell therapy for pediatric B-ALL

  A physician-scientist at St. Jude aims to advance CAR T-cell therapy for children with high-risk B-ALL by testing new donor-derived and enhanced autologous CAR T-cell approaches in early-phase trials.

  NIH research St. Jude Children's Research Hospital · Memphis, United States · NIH-11386624

• Comprehensive look at CAR-T–related brain toxicity in adults

  This grant studies how CAR-T cell therapy can cause acute and lingering brain problems in adults and what signs doctors can watch for.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11380961

• CAR-T therapy targeting glioblastoma and its surroundings

  A patient-facing approach using specially engineered immune cells (CAR-T cells) to attack glioblastoma tumors in the brain and modify the surrounding tumor environment.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11377177

• Engineered CAR-T immune cells to target glioblastoma and its tumor environment

  Engineered CAR-T immune cells are designed to attack glioblastoma tumors and boost the local immune response in adults with GBM.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11377176

• CD5 CAR-T therapy for T-cell lymphoma shows promise in a multi-center trial

  A phase 2 study tests a CD5-targeted CAR-T cell therapy in people with relapsed or refractory T-cell lymphoma to see if it can improve outcomes.

  NIH research March Biosciences INC · Houston, United States · NIH-11370276

• In Vivo Engineering of BCMA CAR T Cells for Multiple Myeloma

  A new NIH grant aims to develop lipid nanoparticle systems that deliver BCMA CAR instructions directly to patients’ immune cells to treat multiple myeloma.

  NIH research Georgia Institute of Technology · Atlanta, United States · NIH-11367782

• BCMA CAR-T therapy with opaganib for ultrahigh risk multiple myeloma

  A first-in-human-style treatment using a patient’s own CAR-T cells plus a targeted drug to help people with very high-risk multiple myeloma live longer and better.

  NIH research University of Oklahoma Hlth Sciences Ctr · Oklahoma City, United States · NIH-11366573

• Enhancing CART-T therapy for B-cell lymphoma with longer-lasting IL-7/IL-15/IL-21 support

  This grant tests a new treatment approach that combines CAR-T cells for large B-cell lymphoma with a long-acting growth factor cocktail to help the CAR-T cells expand and persist.

  NIH research Washington University · Saint Louis, United States · NIH-11365474

• Optimizing gamma/delta CAR-T therapy for bone-ed metastatic prostate cancer

  A patient-focused overview: this grant aims to improve a patient’s own CAR-T cell therapy for bone-dominant, advanced prostate cancer to make it more effective and safer.

  NIH research H. Lee Moffitt Cancer Ctr & Res Inst · Tampa, United States · NIH-11319233

• CAR‑T cells that target glioblastoma and turn immune suppression into a boost

  This project is trying a new CAR‑T cell treatment that targets a common glioblastoma marker and converts the tumor's immune‑suppressing signal into a stimulant to help people with glioblastoma fight their tumors.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11318914

• Remote-controlled PC-CAR T cells for hard-to-treat solid tumors

  A new drug-free approach aims to let immune cells recognize and fight certain solid cancers by remotely adjusting their activity against tumor targets.

  NIH research Mabswitch, INC. · Van Nuys, United States · NIH-11313251

• BAFF-R CAR T cells to treat B-ALL

  A new targeted CAR T-cell therapy against BAFF-R is being studied to help children and adults with B-ALL who have limited options after relapse or resistance to current treatments.

  NIH research Beckman Research Institute/city of Hope · Duarte, United States · NIH-11307086

• Brain scans to predict and prevent CAR‑T related brain injury in children with B‑ALL

  This project uses brain imaging to find signs that predict and help prevent brain side effects after CD19 CAR‑T therapy for children with relapsed or refractory B‑cell acute lymphoblastic leukemia.

  NIH research Children's Hospital of Los Angeles · Los Angeles, United States · NIH-11301859

• Implantable scaffolds to make CAR‑T therapy stronger and cheaper for brain tumors

  This project aims to use a biocompatible implant placed at the tumor site to help CAR‑T immune cells reach and kill glioblastoma cells while reducing the need for repeated, costly infusions.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11294220

• Off-the-shelf CAR T cells to achieve long-term control of HIV

  This project will develop donor-derived CAR T cells for people living with HIV to control or eliminate the virus so they may not need daily antiretroviral drugs.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11285452

• Image-guided, flexible CAR T therapy for solid tumors

  A new, image-guided CAR T approach uses a universal adaptor to target solid tumors and help predict where therapy goes, aiming to reduce relapse and off-target effects.

  NIH research Methodist Hospital Research Institute · Houston, United States · NIH-11282814

• Cooperative CAR T cell therapy for AML patients

  A new CAR T cell approach uses two receptors together to target acute myeloid leukemia while aiming to limit damage to normal blood cells in adults.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11265374

• Blocking fatty acid uptake to help CAR-T work better for relapsed B‑cell ALL

  This research looks at whether stopping leukemia cells from taking up fatty acids can help CD19 CAR‑T therapy work better for children and young adults with relapsed B‑cell acute lymphoblastic leukemia.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-11261188

• Using tumor-targeting viruses to boost CAR T cell treatment for solid tumors

  This work aims to help CAR T cell therapy work better for people with solid tumors by combining CAR T cells with cancer-killing viruses that ramp up the immune response.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11237992

• Simplifying CAR T therapy by programming flu-specific T cells inside the body

  The team plans to deliver CAR instructions into a patient's flu-fighting T cells so they can quickly target multiple myeloma.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11231988

• Combined CAR-T therapy targeting B7-H3 for pancreatic cancer with a safety switch

  This therapy gives engineered T cells that seek out the B7‑H3 protein on pancreatic tumors and includes a built-in safety switch to turn the cells off if needed.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11196743

• Make CAR T therapy last longer for multiple myeloma

  This project tries CAR T cells made from bone marrow immune cells to help people with multiple myeloma stay in remission longer.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11192830

• Making CD45 a single CAR‑T target for many blood cancers

  This project alters immune cells so CD45 can be safely targeted, aiming to create one CAR‑T approach that could treat multiple blood cancers.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11192827

• CAR T cell treatment for metastatic triple-negative breast cancer

  This gives people with metastatic triple-negative breast cancer a personalized treatment using their own T cells modified to target the B7‑H3 protein.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11181670

• Boosting CAR T cell therapy for advanced prostate cancer by blocking androgen signals

  This project looks at whether blocking androgen receptor signals can help a new STEAP1-targeted CAR T‑cell therapy work better for men with advanced, treatment‑resistant prostate cancer.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-11181530

• Understanding short- and long-term brain effects after CAR-T treatment

  This project looks at why some adults who get CAR-T cell treatment develop early or lasting brain and thinking problems by tracking symptoms, brain scans, and blood markers.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11181244

Related topics

Quick answers

How many CAR-T Cell Therapy clinical trials are recruiting right now?

19, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 5 countries. The most sites are in China (9 trials), United States (6 trials), Italy (2 trials), Germany (1 trial), Japan (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 5, Early Phase 1: 3, Phase 1/2: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →